Eric Allémann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Eric Allémann has a total of 186 co-authors. Here are the top co-authors by number of shared publications:
- Olivier Jordan
School of Pharmaceutical Sciences, University of Geneva
21 shared publications - Alexandre Porcello
Development Department, LOUNA REGENERATIVE SA, CH-1228 Plan-les-Ouates, Switzerland
6 shared publications - Alexis Laurent
Regenerative Therapy Unit, Lausanne University Hospital, University of Lausanne, CH-1066 Epalinges, Switzerland
5 shared publications Christian Alexander Seemayer
Department of Clinical Science, Idorsia Pharmaceuticals Ltd., CH-4123 Allschwil, Switzerland
5 shared publicationsPierre Maudens
School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, CH-1211 Geneva 4, Switzerland
5 shared publications- Andrej Babič
School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, 1211 Geneva, Switzerland
4 shared publications
Latest Publications
- Open Access
- 20 February 2026
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 119
Protein-based nanocarrier delivering kartogenin derivative to cartilage matrix for intra-articular treatment of osteoarthritis
- 20 February 2026
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 119
Open AccessProtein-based nanocarrier delivering kartogenin derivative to cartilage matrix for intra-articular treatment of osteoarthritis
- Open Access
- 24 January 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 691, 126613
Enzymatically-responsive hyaluronan–glucose hydrogel supports MSC survival and preserves paracrine function under glucose deprivation
- 24 January 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 691, 126613
Open AccessEnzymatically-responsive hyaluronan–glucose hydrogel supports MSC survival and preserves paracrine function under glucose deprivation
- Open Access
- 31 May 2025
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 22 (7) , 1031-1042
Recent advances in nanocrystals for arthritis drug delivery
More than 500 million people worldwide suffer from arthritis, experiencing daily pain and inflammation. Current treatments for osteoarthritis (OA) and rheumatoid arthritis (RA) are palliative, offering only symptom relief. No disease-modifying OA drugs (DMOADs) capable of restoring joint functionality and regenerating the cartilage matrix have yet been approved by the FDA or EMA. This review highlights recent advances in nanocrystals for arthritis drug delivery, including conventional nanosuspensions and novel transdermal microneedles. Special attention is given to intra-articular DMOADs formulated as nanocrystal-in-microparticles, designed to extend drug release over months. Papers and reviews with the mentioned contents and published over the last 5 years were included in the review process. New DMOADs and disease-modifying antirheumatic drugs (DMARDs) are often poorly water-soluble, limiting their clinical progress. The versatility of nanocrystals and nanosuspensions offers a potential advantage over other types of nanoparticles, as they can be adapted to various delivery systems, administration routes, and types of arthritis. Due to the avascular nature of cartilage, exploring the intra-articular route for OA management is essential. Implementing cartilage-targeted strategies or using stimuli-responsive hydrogels can further enhance their therapeutic potential.
- 31 May 2025
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 22 (7) , 1031-1042
Open AccessRecent advances in nanocrystals for arthritis drug delivery
More than 500 million people worldwide suffer from arthritis, experiencing daily pain and inflammation. Current treatments for osteoarthritis (OA) and rheumatoid arthritis (RA) are palliative, offering only symptom relief. No disease-modifying OA drugs (DMOADs) capable of restoring joint functionality and regenerating the cartilage matrix have yet been approved by the FDA or EMA. This review highlights recent advances in nanocrystals for arthritis drug delivery, including conventional nanosuspensions and novel transdermal microneedles. Special attention is given to intra-articular DMOADs formulated as nanocrystal-in-microparticles, designed to extend drug release over months. Papers and reviews with the mentioned contents and published over the last 5 years were included in the review process. New DMOADs and disease-modifying antirheumatic drugs (DMARDs) are often poorly water-soluble, limiting their clinical progress. The versatility of nanocrystals and nanosuspensions offers a potential advantage over other types of nanoparticles, as they can be adapted to various delivery systems, administration routes, and types of arthritis. Due to the avascular nature of cartilage, exploring the intra-articular route for OA management is essential. Implementing cartilage-targeted strategies or using stimuli-responsive hydrogels can further enhance their therapeutic potential.
- Open Access
- 4 May 2025
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 678, 125678
Evaluation of peanut tolerance in sensitized mice through intradermal allergen delivery with adjuvants
- 4 May 2025
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 678, 125678
Open AccessEvaluation of peanut tolerance in sensitized mice through intradermal allergen delivery with adjuvants
- Open Access
- 18 April 2025
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 121 (6) , 915-928
Enhanced intracranial aneurysm development in a rat model of polycystic kidney disease
Aims: Polycystic kidney disease (PKD) patients have a high intracranial aneurysms (IAs) incidence and risk of rupture. The mechanisms that make PKD patients more vulnerable to IA disease are still not completely understood. The PCK rat is a well-known PKD model and has been extensively used to study cyst development and kidney damage. Here, we used this rat model to study IA induction and vulnerability. Methods and results: IAs were induced in wild-type (WT) and PCK rats and their incidence was followed. Variation in the anatomy of the circle of Willis was studied in PCK rats and PKD patients. Immunohistochemistry was performed in rat IAs and in human ruptured and unruptured IAs from patients enrolled in the @neurIST observational cohort. An increased frequency of fatal aortic dissection was unexpectedly observed in PCK rats, which was due to modifications in the elastic architecture of the aorta in combination with the induced hypertension. Interestingly, IAs developed faster in PCK rats compared to WT rats. Variations in the anatomy of the circle of Willis were identified in PCK rats and PKD patients, a risk factor that may (in part) explain the higher IA incidence found in these groups. At 2 weeks after induction, the endothelium of IAs from PCK rats showed a decrease in the tight junction proteins zonula occludens-1 and claudin-5. Furthermore, the Type III collagen content was lower in IAs of PCK rats at 4 weeks post-surgery. The decrease in tight junction proteins was also observed in the endothelium of human ruptured IAs compared to unruptured IAs. Conclusion: Our study showed that PCK rats are more sensitive to IA induction. Variations in the anatomy of the circle of Willis and impaired regulation of tight junction proteins might put PCK rats and PKD patients more at risk of developing vulnerable IAs.
- 18 April 2025
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 121 (6) , 915-928
Open AccessEnhanced intracranial aneurysm development in a rat model of polycystic kidney disease
Aims: Polycystic kidney disease (PKD) patients have a high intracranial aneurysms (IAs) incidence and risk of rupture. The mechanisms that make PKD patients more vulnerable to IA disease are still not completely understood. The PCK rat is a well-known PKD model and has been extensively used to study cyst development and kidney damage. Here, we used this rat model to study IA induction and vulnerability. Methods and results: IAs were induced in wild-type (WT) and PCK rats and their incidence was followed. Variation in the anatomy of the circle of Willis was studied in PCK rats and PKD patients. Immunohistochemistry was performed in rat IAs and in human ruptured and unruptured IAs from patients enrolled in the @neurIST observational cohort. An increased frequency of fatal aortic dissection was unexpectedly observed in PCK rats, which was due to modifications in the elastic architecture of the aorta in combination with the induced hypertension. Interestingly, IAs developed faster in PCK rats compared to WT rats. Variations in the anatomy of the circle of Willis were identified in PCK rats and PKD patients, a risk factor that may (in part) explain the higher IA incidence found in these groups. At 2 weeks after induction, the endothelium of IAs from PCK rats showed a decrease in the tight junction proteins zonula occludens-1 and claudin-5. Furthermore, the Type III collagen content was lower in IAs of PCK rats at 4 weeks post-surgery. The decrease in tight junction proteins was also observed in the endothelium of human ruptured IAs compared to unruptured IAs. Conclusion: Our study showed that PCK rats are more sensitive to IA induction. Variations in the anatomy of the circle of Willis and impaired regulation of tight junction proteins might put PCK rats and PKD patients more at risk of developing vulnerable IAs.
- Open Access
- 20 January 2025
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 671, 125250
Rational design and analytical characterization of self-assembling poly(N‑isopropylacrylamide) and poly(2‑alkyl‑2‑oxazoline) hyaluronic acid copolymers
- 20 January 2025
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 671, 125250
Open AccessRational design and analytical characterization of self-assembling poly(N‑isopropylacrylamide) and poly(2‑alkyl‑2‑oxazoline) hyaluronic acid copolymers
- Open Access
- 26 April 2024
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 657, 124139
Hyaluronan-based hydrogel delivering glucose to mesenchymal stem cells intended to treat osteoarthritis
- 26 April 2024
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 657, 124139
Open AccessHyaluronan-based hydrogel delivering glucose to mesenchymal stem cells intended to treat osteoarthritis
- Open Access
- 7 March 2024
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 14 (12) , 3438-3451
Nanocrystals and nanosuspensions: an exploration from classic formulations to advanced drug delivery systems
Nanocrystals and nanosuspensions have become realistic approaches to overcome the formulation challenges of poorly water-soluble drugs. They also represent a less-known but versatile platform for multiple therapeutic applications. They can be integrated into a broad spectrum of drug delivery systems including tablets, hydrogels, microneedles, microparticles, or even functionalized liposomes. The recent progresses, challenges, and opportunities in this field are gathered originally together with an informative case study concerning an itraconazole nanosuspension-in-hydrogel formulation. The translational aspects, historical and current clinical perspectives are also critically reviewed here to shed light on the incoming generation of nanocrystal formulations.
- 7 March 2024
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 14 (12) , 3438-3451
Open AccessNanocrystals and nanosuspensions: an exploration from classic formulations to advanced drug delivery systems
Nanocrystals and nanosuspensions have become realistic approaches to overcome the formulation challenges of poorly water-soluble drugs. They also represent a less-known but versatile platform for multiple therapeutic applications. They can be integrated into a broad spectrum of drug delivery systems including tablets, hydrogels, microneedles, microparticles, or even functionalized liposomes. The recent progresses, challenges, and opportunities in this field are gathered originally together with an informative case study concerning an itraconazole nanosuspension-in-hydrogel formulation. The translational aspects, historical and current clinical perspectives are also critically reviewed here to shed light on the incoming generation of nanocrystal formulations.
- Top Cited PapersOpen Access
Clinical Perspectives on the Injectability of Cross-Linked Hyaluronic Acid Dermal Fillers: A Standardized Methodology for Commercial Product Benchmarking with Inter-Injector Assessments
The injectability of cross-linked hyaluronic acid (HA) dermal fillers is influenced by polymer concentration, polymer cross-linking type and degree, the presence of lidocaine or other functional excipients, types of syringes, and injection techniques. Finished product injectability constitutes a critical quality attribute for clinical injectors, as it strongly influences product applicability and ease of use in aesthetic medicine. While injectable product extrusion force specifications are provided by the respective device manufacturers, the qualitative informative value of such datasets is low for injectors wishing to compare product brands and technologies from an injectability standpoint. Therefore, the present study comparatively assessed 28 cross-linked HA dermal fillers (JUVÉDERM®, Restylane®, BELOTERO®, TEOSYAL RHA®, and STYLAGE® brands) using various injectability benchmarking setups for enhanced clinical-oriented relevance. Manual product injections were performed by three specialized and experienced clinicians, whereas automatic product extrusion was performed using a Texture Analyzer instrument. The various hydrogel products were injected into ex vivo human skin and into SimSkin® cutaneous equivalents to appropriately account for injection-related counterpressure. The injectability results revealed important variability between and within product brands, with a strong influence of the local anesthetic lidocaine, HA contents, and needle gauge size. Critical appraisals of the investigated products were performed, notably from manufacturing process-based and clinical ease of application-based standpoints, centered on respective experimental injectability quality levels. Generally, it was confirmed that each HA-based dermal filler product requires specific expertise for optimal injection, mainly due to differing viscoelastic characteristics and injectability attributes. Overall, the present study set forth evidence-based and clinical-oriented rationale elements confirming the importance for injectors to work with injectable products with which they are experienced and comfortable to optimize clinical results.
Top Cited PapersOpen AccessClinical Perspectives on the Injectability of Cross-Linked Hyaluronic Acid Dermal Fillers: A Standardized Methodology for Commercial Product Benchmarking with Inter-Injector Assessments
The injectability of cross-linked hyaluronic acid (HA) dermal fillers is influenced by polymer concentration, polymer cross-linking type and degree, the presence of lidocaine or other functional excipients, types of syringes, and injection techniques. Finished product injectability constitutes a critical quality attribute for clinical injectors, as it strongly influences product applicability and ease of use in aesthetic medicine. While injectable product extrusion force specifications are provided by the respective device manufacturers, the qualitative informative value of such datasets is low for injectors wishing to compare product brands and technologies from an injectability standpoint. Therefore, the present study comparatively assessed 28 cross-linked HA dermal fillers (JUVÉDERM®, Restylane®, BELOTERO®, TEOSYAL RHA®, and STYLAGE® brands) using various injectability benchmarking setups for enhanced clinical-oriented relevance. Manual product injections were performed by three specialized and experienced clinicians, whereas automatic product extrusion was performed using a Texture Analyzer instrument. The various hydrogel products were injected into ex vivo human skin and into SimSkin® cutaneous equivalents to appropriately account for injection-related counterpressure. The injectability results revealed important variability between and within product brands, with a strong influence of the local anesthetic lidocaine, HA contents, and needle gauge size. Critical appraisals of the investigated products were performed, notably from manufacturing process-based and clinical ease of application-based standpoints, centered on respective experimental injectability quality levels. Generally, it was confirmed that each HA-based dermal filler product requires specific expertise for optimal injection, mainly due to differing viscoelastic characteristics and injectability attributes. Overall, the present study set forth evidence-based and clinical-oriented rationale elements confirming the importance for injectors to work with injectable products with which they are experienced and comfortable to optimize clinical results.